Simultaneous modulation of the intrinsic and extrinsic pathways by simvastatin in mediating prostate cancer cell apoptosis
- Anna Goc†1, 2,
- Samith T Kochuparambil†1, 2, 3,
- Belal Al-Husein1, 2,
- Ahmad Al-Azayzih1, 2,
- Shuaib Mohammad1 and
- Payaningal R Somanath1, 2, 3, 4Email author
© Goc et al.; licensee BioMed Central Ltd. 2012
Received: 14 April 2012
Accepted: 11 September 2012
Published: 14 September 2012
Recent studies suggest the potential benefits of statins as anti-cancer agents. Mechanisms by which statins induce apoptosis in cancer cells are not clear. We previously showed that simvastatin inhibit prostate cancer cell functions and tumor growth. Molecular mechanisms by which simvastatin induce apoptosis in prostate cancer cells is not completely understood.
Effect of simvastatin on PC3 cell apoptosis was compared with docetaxel using apoptosis, TUNEL and trypan blue viability assays. Protein expression of major candidates of the intrinsic pathway downstream of simvastatin-mediated Akt inactivation was analyzed. Gene arrays and western analysis of PC3 cells and tumor lysates were performed to identify the candidate genes mediating extrinsic apoptosis pathway by simvastatin.
Data indicated that simvastatin inhibited intrinsic cell survival pathway in PC3 cells by enhancing phosphorylation of Bad, reducing the protein expression of Bcl-2, Bcl-xL and cleaved caspases 9/3. Over-expression of PC3 cells with Bcl-2 or DN-caspase 9 did not rescue the simvastatin-induced apoptosis. Simvastatin treatment resulted in increased mRNA and protein expression of molecules such as TNF, Fas-L, Traf1 and cleaved caspase 8, major mediators of intrinsic apoptosis pathway and reduced protein levels of pro-survival genes Lhx4 and Nme5.
Our study provides the first report that simvastatin simultaneously modulates intrinsic and extrinsic pathways in the regulation of prostate cancer cell apoptosis in vitro and in vivo, and render reasonable optimism that statins could become an attractive anti-cancer agent.
KeywordsProstate cancer Simvastatin Docetaxel Apoptosis Bcl-2 Fas-L
Statins, the cholesterol lowering drugs, are some of the most commonly prescribed medications. Recently, attention has focused on the development of statins as therapeutic agents for the treatment of solid and hematological cancers . Statins elicit pleiotropic effects on various cell types and differentially modulate cellular functions such as cell migration, proliferation, cell survival and apoptosis in normal and malignant cells . Lipophilicity, dose and duration of the treatment as well as cell type are all determining factors on the specific effect of a statin on the outcome of a cell function. According to the American Cancer Society, prostate cancer is the most commonly diagnosed cancer and the second leading cause of cancer death in American men. Many recent clinical studies have indicated that use of statins is associated with >50% reduction in prostate cancer deaths [3, 4]. Our previous study showed that simvastatin, a lipophilic statin inhibited multiple prostate cancer cell functions in vitro such as migration, proliferation, cell survival and colony formation as well as tumor growth in a nude mouse xenograft in vivo, mainly via inhibition of Akt pathway . However, exact molecular mechanisms by which statins modulate each of the prostate cancer cell function are not clear.
One of the factors that determine the efficacy of a cancer drug is its ability to inhibit cancer cell survival and induce apoptosis. Meantime, a major concern over the use of anti-cancer drugs for therapy is the side-effects that they can inflict on normal cells. For a very long time, scientists are on the search of anti-cancer agents that specifically target tumor cells with no or minimum effects on normal cells. A very recent study indicates that simvastatin, at doses that we had previously shown to induce apoptosis in prostate cancer cells , does not compromise cell survival in normal airway epithelial and fibroblast cells, while inducing apoptosis in breast, hepatocellular and lung carcinoma cells . Although this study provides the necessary assurance that simvastatin may be a potential drug for specifically targeting cancer cells for therapy, the molecular mechanisms by which simvastatin induces apoptosis in cancer cells remains to be determined.
Bcl-2-mediated, mitochondria associated cell survival pathway (intrinsic pathway) is one of the major pathways that are targeted for inducing apoptosis in cancer cells. In addition to this, another major pathway that promotes apoptosis in cancer cells is the death receptor-mediated pathway (extrinsic pathway) . Tumor necrosis factor (TNF), TNF-related apoptosis inducing ligand (TRAIL), Fas-ligand (Fas-L), TNF-related factor-1 and 2 (Traf1/2) etc. are some of the key molecules that belong to the extrinsic pathway or death receptor signaling that are known to be de-regulated in cancers [8, 9]. While inhibition of Bcl-2-mediated intrinsic pathway leads to the release of cytochrome c from the mitochondria to the cytosol, resulting in the activation of caspases 9 and 3, death receptor-mediated extrinsic pathway involves caspases 10 and 8 in inducing apoptosis . A pre-requisite for the latter is the formation of a death-inducing signaling complex (DISC) between Fas-assciated death domain (FADD) and pro-caspase 8 . Resulting cleavage of pro-caspase 8 to active cleaved caspase 8 leads to the activation of downstream caspases such as caspase 3 .
Until recently, docetaxel-based chemotherapy is the only available treatment option for the androgen-insensitive prostate cancer patients and is shown to modestly improve survival , marking the first real advance after the identification of therapeutic castration by Charles Huggins in 1941 . Docetaxel (Taxotere®) acts via suppression of microtubule assembly and disassembly, microtubule bundling and inhibition of Bcl-2, leading to apoptosis . However, use of docetaxel is associated with a number of serious side-effects due to yet unknown reasons [15, 16]. According to many reports doses of statins, even 50 times higher than the prescribed doses for the treatment of cardiovascular diseases, did not inflict any serious side-effects or toxicity to liver and kidney in men [17–19]. In the current study, we investigated the various mechanisms by which simvastatin induce apoptosis in prostate cancer cells as compared to the known effects of docetaxel treatment. Our study indicates that simvastatin induces apoptosis in prostate cancer cells in vitro and prostate tumor xenograft in vivo by simultaneously modulating intrinsic and extrinsic apoptotic pathways. These results suggest that simvastatin can be developed as an important drug for the treatment of prostate cancer either alone or in combination with reduced doses of chemotherapeutic drugs such as docetaxel to improve the efficacy and reduce the side-effects.
Cell lines, reagents, and antibodies
Human PC3 and LNCaP cell lines were obtained from ATCC (Manassas, VA) and maintained in DMEM High Glucose (HyClone) with 10% fetal bovine serum (FBS), 100 units/ml penicillin, and 100 μg/ml streptomycin in 5% CO2 humidified atmosphere at 37°C. Primary antibodies against pBad, Bcl-2, Bcl-xL, Bim, cleaved caspase 3, cleaved caspase 9, cleaved caspase 8, cytocrocme c, Fas-L, survivin and Traf1 were purchased from Cell Signaling (Boston, MA). Primary antibodies anti-Nme5 was obtained from Abcam (Cambridge, MA/ San Francisco, CA), anti-Trp53inp1 was from R&D (Minneapolis, MN) and anti-β-actin was from Sigma (St Louis, MO). Anti-mouse and anti-rabbit HRP conjugated secondary antibodies were obtained from BioRad (Hercules, CA). Docetaxel and simvastatin were purchased from Sigma (St Louis, MO). Simvastatin was activated in the laboratory using the manufacturer’s instructions.
Adenoviral particles for Bcl-2 and DN-Caspase-9 used for the experiments were obtained from Vector BioLabs (Eagleville, PA). For adeno-infections, PC3 cells were grown until reaching 75 % of confluence in 6-well plates. Next, cells were washed with 1X PBS and 1 ml of DMEM without FBS, supplemented with 10 μg of polybrene was added, followed 5X109 PFU/ml of adeno-Bcl-2 virus and/or 1X1010 PFU/ml of andeno-CMV-caspase9 virus. After 48 hours cells were lysed, protein levels were quantified using DL protein assay (Bio-Rad, Hercules, CA) and subjected to western blot analysis.
Trypan blue viability assessment
In the trypan blue method, cells were grown to confluence in DMEM with 10% FBS. The cells were treated with 25 μM simvastatin, 10 nM docetaxel, or a combination of both in DMEM. After 24h, cells were collected and re-suspended in PBS with 0.4% trypan blue solution. Total cells and trypan blue-stained (i.e., nonviable) cells were counted, and the percentage of nonviable cells was calculated.
Cytoplasmic histone-associated DNA fragments were quantified by using the Cell Death Detection ELISAPLUS kit (Roche Applied Science, Indianapolis, IN) according to the manufacturer's protocol. Briefly, PC3 cells were plated in 96-well plate at a density of either 104 cells/well. After 24h, the cells were treated with 25 μM simvastatin and/or 10 nM docetaxel for 16h in DMEM containing 10% FBS. Control cells received 0.1% DMSO (vehicle control). Cells were lysed and centrifuged at 200g for 10 min, and the collected supernatant was subjected to ELISA. The absorbance was measured at 405 nm (reference wavelength, 492 nm).
Caspase-9 activity assay
Caspase-9 activity assay were performed using Caspase-Glo® 9 Assay kit according to the manufacturer’s protocol (Promega, Madison, WI). Briefly, PC3 cells were either treated with 25 μM simvastatin, 10 nM docetaxel, and a combination of both, or infected with 5X109 PFU/ml of adeno-Bcl-2 virus and/or 1X1010 PFU/ml of adeno-DN-caspase9 virus particles. After plating PC3 cells were plated on a 96-well plate at the density of 2.5x104, 100 μl of Caspase-Glo® 9 Reagent was added to each well and cells were incubated in room temperature for 2.5 h followed by the luminescence measurement using an ELISA plate reader. The data are presented as mean ± S.D.
In vivonude mouse tumor xenograft model
All animal procedures listed in this article were performed as per the protocol approved by the Institutional Animal Care and Use Committee at the Charlie Norwood Veterans Affairs Medical Center, Augusta, GA (protocol 09-07-011, dated July 10, 2009). PC3 cells were grown to confluence in 250-ml flasks. Cells were re-suspended in PBS to a concentration of 106/ml. Cell suspension (1 μl) was injected subcutaneously in 6- to 8-week-old nude mice (athymic nude mice; Harlan, Indianapolis, IN). The mice were subjected to intraperitoneal injections of simvastatin at a dose of 2 mg/kg body weight every 12h for 2 weeks. The respective controls were injected intraperitoneally with 0.9% saline every 12h. Mice were sacrificed on day 14, and tumors were dissected, weighed, and snap frozen using dry ice for further processing to use on western or qRT-PCR.
Terminal deoxynucleotidyl transferase-mediated dUTP nick end labeling (TUNEL) assay
The TUNEL assay for in situ detection of apoptosis was performed by using the ApopTag® Fluorescein In Situ Apoptosis detection kit (Millipore, MA) according to the manufacturer’s instructions. Cells were plated in 24-well flat bottom plates at a density of 1 x 105 cells/well and treated with 25 μM simvastatin, 10nM docetaxel or a combination of both for 24h. Following treatments, cells were fixed in 2% paraformaldehyde at 4°C for 30 min. Fixed cells were then permeabilized in 0.1% Triton X-100 and labeled with fluorescein 12-dUTP using terminal deoxynucleotidyl transferase. Nuclei were counterstained with DAPI. Frozen nude mouse prostate tumor (PC3) xenograft sections were also processed accordingly. Cells/tissue sections were analyzed for apoptotic cells with localized green fluorescence using an inverted fluorescence microscope (Zeiss Axiovert100M, Carl Zeiss, Germany).
QReal-time PCR arrays
PC3 cells were grown until reaching 75% of confluence in 6-well plates and subjected to RNA isolation, followed cDNA synthesis and qPCR quantification. Briefly, cells were lysed and RNA was isolated according to manufacturer’s protocol using RNAese Mini Plus Kit (Qiagen, Valencia, CA). Next, 25 μl of cDNA was produced by RT2 First Strand Kit (SABioscience, Frederick, MD), mixed with qPCR SyberGreen master mix and loaded into Human Apoptosis RT2 Profiler PCR Array plate (SABiosciences, Frederick, MD). Reading was completed in Eppendorf Mastercycler realplex 2 instrument.
Western blot analysis
PC3 cells were cultured in 6-well plates to reach a monolayer. At that point, the cells were treated with 25 μM simvastatin and/or 10 nM docetaxel in DMEM supplemented with 10% FBS. Control cells received 0.1% of DMSO. Whole cell lysates were prepared using lysis buffer [50 mM Tris–HCl (pH=7.4), 1% TritonX-100, 150mM NaCl, 1mM EDTA, 2mM Na3VO4, and 1X Complete protease inhibitors (Roche Applied Science, Indianapolis, IN)]. Tumors isolated from mice with C53BL/6 background treated with 2mg/kg simvastatin for 11 days, were first snap frozen in liquid nitrogen and then pulverized with mortar and piston. Next, tissues lysates were prepared using lysis buffer. The protein concentration was measured by the DL protein assay (Bio-Rad, Hercules, CA). 60 μg/μl of protein was subjected to western blot analysis according to standard Laemmli’s method.
Mean activities were calculated from 3–5 independent experiments done at least in triplicates. The Student’s two-tailed t test was used to determine significant differences between treatment and control values.
Simvastatin induces cell death and apoptosis in prostate cancer cells
Simvastatin inhibits Bcl-2-mediated intrinsic pathway in prostate cancer cells
Simvastatin induces apoptosis in prostate tumor xenografts via inhibition of intrinsic cell survival pathway
Prostate cancer cells over-expressing Bcl-2 and/or DN-Caspase 9 are not resistant to simvastatin induced apoptosis
Simvastatin modulates expression of genes involved in the death receptor-mediated apoptotic pathway in prostate cancer cells
Genes modulated by simvastatin in PC3 cells as identified by qRT-PCR arrays
Change (X fold)
Activating transcription factor 5
B-cell leukemia/lymphoma 2
Bcl2-like 1 and 2
Baculoviral IAP repeat-containing 1a
Baculoviral IAP repeat-containing 3
Baculoviral IAP repeat-containing 5
Cell death-inducing DNA fragmentation factor, alpha subunit-like effector A
Defender against cell death 1
Fas (TNFRSF6)-associated via death domain
Fas ligand (TNF superfamily, member 6)
LIM homeobox protein 4
Non-metastatic cells 5, protein expressed in (nucleoside-diphosphate kinase)
Nucleolar protein 3 (apoptosis repressor with CARD domain)
PYD and CARD domain containing
Tumor necrosis factor
Tumor necrosis factor receptor superfamily, member 10b
Tumor necrosis factor (ligand) superfamily, member 10
Tnf receptor-associated factor 1
Transformation related protein 53 inducible nuclear protein 1
Simvastatin, but not docetaxel is involved in the activation of Fas-L mediated extrinsic pathway in prostate cancer cells and tumor xenografts
Because of its ‘crossroad’ role in multiple essential signaling pathways in cancer cell maintenance, and its enhanced expression and/or activation in multiple cancer cells as compared to normal, Akt kinase is being actively pursued as a novel target for cancer therapy [20–23]. However, since Akt is essential for many normal cell functions [24–26], cell survival in particular, targeting Akt for cancer therapy is a bottle neck due to the serious side-effects associated with it. This asks for novel therapies that can inflict a significant but selective effect on cancer cells in inhibiting pathways like Akt without affecting the normal functioning of extra-tumor tissues. Many recently published reports suggest that statins, at certain higher doses, can be a selective and very efficient drug to treat cancers without inflicting any major side-effects [17–19]. We previously showed that simvastatin, at a dose ~5 times higher than the therapeutic dose prescribed for the treatment of cardiovascular diseases, significantly inhibited Akt activity in PC3 tumor cells and prostate tumor xenograft growth in vivo. Another recent report indicated that at similar doses, simvastatin induced apoptosis in breast cancer cells, but not in normal airway epithelial cells or fibroblasts . Thus, the ability of simvastatin to selectively inhibit Akt activity and induce apoptosis in prostate cancer cells without affecting the normal cells makes it an attractive candidate for drug re-purposing for cancer therapy.
Many of the effects of simvastatin on prostate cancer cell apoptosis can be credited to its ability to inhibit Akt activity. Akt is known to enhance the intrinsic mitochondria-associated cell survival pathway in cancer cells via increased phosphorylation of Bad and enhanced expression of Bcl-2 and Bcl-xL . Upon inhibition of Akt by simvastatin in PC3 cells, we saw reduced phosphorylation of Bad, decreased expression of Bcl-2 and Bcl-xL, associated with increased expression of Bim as well as cleaved caspases 9 and 3. Activated caspase 3 is expected to further cleave PARP in inducing apoptosis . Inhibition of Bcl-2-mediated pathway by statins has also been shown by other labs in multiple cancer types [6, 27, 28]. However, our attempt to rescue the PC3 cells from apoptosis by re-constituting the Bcl-2 pathway by over-expressing PC3 cells with Bcl-2 and/or DN-caspase 9 did not reverse the simvastatin-induced apoptosis. This suggested that pathways other than intrinsic survival pathway are involved in simvastatin-induced apoptosis in prostate cancer cells.
On the other end, gene arrays as well as western analysis of cell and tumor lysates identified a number of novel candidates that are involved in the simvastatin-induced apoptosis in prostate cancer cells. One of the pro-survival proteins that were found to be less expressed in simvastatin-treated PC3 cells was survivin, which is also associated with mitochondria-associated cell survival pathway. Survivin is highly expressed in many cancer cells , including prostate cancer cells [30, 31]. Regulation of survivin expression in multiple experimental models has been linked to increase in Akt activity . In prostate cancer cells, survivin expression has been shown to be regulated by IGF-1 stimulated Akt-mTOR signaling , which Is impaired upon simvastatin treatment . A second pro-survival molecule that is significantly less expressed in simvastatin-treated PC3 cells is non-metastatic cells 5 (Nme5). Nme5, also known as the inhibitor of p53-induced apoptosis-beta (IPIA-beta) is known to confer protection from cell death by Bax and alter the cellular levels of several anti-oxidant enzymes such as Gpx5 . A third molecule that was significantly less expressed in PC3 cells with simvastatin treatment was Lhx4, a molecule abundantly expressed in many cancers [35, 36], but exact function is yet to be determined. Other molecules that are de-regulated with simvastatin-treatment in PC3 cells include CD70 (TNFRSF7), CD40, caspase-1, Trp53inp1 and TNFRSF10b etc. (Table 1).
Another mechanism by which apoptosis can be triggered in cancer cells is via signaling by death receptor members that belong to the tumor necrosis factor receptor super-family . Among the eight members of the death receptor family, most common are the TNF receptor 1 (TNFR1 or DR1) and Fas (CD95 or DR2) . Our gene array results indicated an increase in TNF and Fas-L in prostate cancer cells, which are ligands for TNFR1 and Fas, respectively, with simvastation treatment. Furthermore, increase in the expression of other molecules associated with the Fas receptor such as Traf1 and Fas (TNFRSF6)-associated via death domain (FADD) leading to activation of caspase-8 was also observed in PC3 cells and/or tumor lysates with simvastatin treatment. In order to induce apoptosis, TNF and Fas-L utilizes two different death receptor signaling complexes. Fas-L-mediated mechanism comprises the death-inducing signaling complexes (DISCs) that are formed at the CD95 or Fas receptor between Fas-assciated death domain (FADD) and pro-caspases 10 and 8 . Formation of DISC results in the activation of caspases 10 and 8, which place a central role in the transduction of death signal [10, 38]. TNF induces apoptosis via a mechanism different from Fas-induced cell death involving two different signaling complexes . Complex-I is formed at the membrane and comprises TNF, TNFR1, receptor-interacting protein (RIP), TNFR-associated death domain (TRADD), TNFR-associated factors 1 and 2 (Traf-1/2) etc. and acts through a JNK-dependent mechanism. Complex-II, also known as traddosome, consists of FADD and caspase 8, which are absent in complex-I . An increase in the levels of cleaved caspase 8 in the PC3 tumor lysates from simvastation-treated mice indicate that one or both of the Fas-L and TNF-mediated death-receptor signaling pathway is involved in simvastatin-induced apoptosis in prostate cancer cells.
In conclusion, our results have demonstrated that treatment with simvastatin induces apoptosis in prostate cancer cells in vitro and tumor xenograft in vivo via simultaneous modulation of mitochondria-associated intrinsic pathway that comprises Bcl-2, Bcl-xL and caspases 9 and 3 as well as Fas-L and TNF-dependent extrinsic death receptor pathway involving caspase-8. Our study reinforces the rationale of selective pharmacologic inhibition of prostate cancer cell survival using statins and suggests re-purposing of lipophilic statins such as simvastatin for prostate cancer therapy in humans. Alternatively, statins may also be used in combination with other cytotoxic agents such as docetaxel to improve the drug efficacy and reduce the side-effects.
B-Cell lymphoma extra-large
Death-inducing signaling complex
Fas-assciated death domain
LIM homeobox protein-4
Non-metastatic cells 5
Tumor Necrosis factor
Tumor Necrosis factor receptor superfamily
TNF-related apoptosis inducing ligand
TNFR-associated death domain
TNF-related factor 1 and 2
Terminal deoxynucleotidyl transferase-mediated dUTP nick end labeling.
We acknowledge the funds provided by the University of Georgia Research Foundation, Wilson Pharmacy Foundation and UGA College of Pharmacy through intramural grants to PRS. Authors also acknowledge partial support from National Institutes of Health grant (R01HL103952) and American Heart Association Scientist Development Grant (0830326N) to PRS.
- Jakobisiak M, Golab J: Statins can modulate effectiveness of antitumor therapeutic modalities. Med Res Rev. 2010, 30: 102-135.PubMed
- Liao JK, Laufs U: Pleiotropic effects of statins. Annu Rev Pharmacol Toxicol. 2005, 45: 89-118. 10.1146/annurev.pharmtox.45.120403.095748.PubMed CentralView ArticlePubMed
- Hamilton RJ, Banez LL, Aronson WJ, Terris MK, Platz EA, Kane CJ, Presti JC, Amling CL, Freedland SJ: Statin medication use and the risk of biochemical recurrence after radical prostatectomy: results from the Shared Equal Access Regional Cancer Hospital (SEARCH) Database. Cancer. 2010, 116: 3389-3398. 10.1002/cncr.25308.PubMed CentralView ArticlePubMed
- Marcella SW, David A, Ohman-Strickland PA, Carson J, Rhoads GG: Statin use and fatal prostate cancer: A matched case–control study. Cancer. 2012, 118 (16): 4046-4052. 10.1002/cncr.26720.PubMed CentralView ArticlePubMed
- Kochuparambil ST, Al-Husein B, Goc A, Soliman S, Somanath PR: Anticancer efficacy of simvastatin on prostate cancer cells and tumor xenografts is associated with inhibition of Akt and reduced prostate-specific antigen expression. J Pharmacol Exp Ther. 2011, 336: 496-505. 10.1124/jpet.110.174870.View ArticlePubMed
- Spampanato C, De Maria S, Sarnataro M, Giordano E, Zanfardino M, Baiano S, Carteni M, Morelli F: Simvastatin inhibits cancer cell growth by inducing apoptosis correlated expression. Int J Oncol. 2012, 40: 935-941.PubMed CentralPubMed
- Fulda S, Debatin KM: 5-Aza-2′-deoxycytidine and IFN-gamma cooperate to sensitize for TRAIL-induced apoptosis by upregulating caspase-8. Oncogene. 2006, 25: 5125-5133.View ArticlePubMed
- French LE, Tschopp J: Protein-based therapeutic approaches targeting death receptors. Cell Death Differ. 2003, 10: 117-123. 10.1038/sj.cdd.4401185.View ArticlePubMed
- Wajant H: Death receptors. Essays Biochem. 2003, 39: 53-71.View ArticlePubMed
- Peter ME, Krammer PH: The CD95(APO-1/Fas) DISC and beyond. Cell Death Differ. 2003, 10: 26-35. 10.1038/sj.cdd.4401186.View ArticlePubMed
- Micheau O, Tschopp J: Induction of TNF receptor I-mediated apoptosis via two sequential signaling complexes. Cell. 2003, 114: 181-190. 10.1016/S0092-8674(03)00521-X.View ArticlePubMed
- Massard C, Fizazi K: Targeting continued androgen receptor signaling in prostate cancer. Clin Cancer Res. 2011, 17: 3876-3883. 10.1158/1078-0432.CCR-10-2815.View ArticlePubMed
- Huggins C, Hodges CV: Studies on prostatic cancer: I. The effect of castration, of estrogen and of androgen injection on serum phosphatases in metastatic carcinoma of the prostate. 1941. J Urol. 2002, 168: 9-12. 10.1016/S0022-5347(05)64820-3.View ArticlePubMed
- Herbst RS, Khuri FR: Mode of action of docetaxel - a basis for combination with novel anticancer agents. Cancer Treat Rev. 2003, 29: 407-415. 10.1016/S0305-7372(03)00097-5.View ArticlePubMed
- Eckhoff L, Nielsen M, Moeller S, Knoop A: TAXTOX - a retrospective study regarding the side effects of docetaxel given as part of the adjuvant treatment to patients with primary breast cancer in Denmark from 2007 to 2009. Acta Oncol. 2011, 50: 1075-1082. 10.3109/0284186X.2011.602111.View ArticlePubMed
- Pivot X, Schneeweiss A, Verma S, Thomssen C, Passos-Coelho JL, Benedetti G, Ciruelos E, von Moos R, Chang HT, Duenne AA, Miles DW: Efficacy and safety of bevacizumab in combination with docetaxel for the first-line treatment of elderly patients with locally recurrent or metastatic breast cancer: results from AVADO. Eur J Cancer. 2011, 47: 2387-2395. 10.1016/j.ejca.2011.06.018.View ArticlePubMed
- Thibault A, Samid D, Tompkins AC, Figg WD, Cooper MR, Hohl RJ, Trepel J, Liang B, Patronas N, Venzon DJ, et al: Phase I study of lovastatin, an inhibitor of the mevalonate pathway, in patients with cancer. Clin Cancer Res. 1996, 2: 483-491.PubMed
- van der Spek E, Bloem AC, van de Donk NW, Bogers LH, van der Griend R, Kramer MH, de Weerdt O, Wittebol S, Lokhorst HM: Dose-finding study of high-dose simvastatin combined with standard chemotherapy in patients with relapsed or refractory myeloma or lymphoma. Haematologica. 2006, 91: 542-545.PubMed
- Holstein SA, Knapp HR, Clamon GH, Murry DJ, Hohl RJ: Pharmacodynamic effects of high dose lovastatin in subjects with advanced malignancies. Cancer Chemother Pharmacol. 2006, 57: 155-164. 10.1007/s00280-005-0013-8.View ArticlePubMed
- Somanath PR, Vijai J, Kichina JV, Byzova T, Kandel ES: The role of PAK-1 in activation of MAP kinase cascade and oncogenic transformation by Akt. Oncogene. 2009, 28: 2365-2369. 10.1038/onc.2009.114.PubMed CentralView ArticlePubMed
- Goc A, Al-Husein B, Kochuparambil ST, Liu J, Heston WW, Somanath PR: PI3 kinase integrates Akt and MAP kinase signaling pathways in the regulation of prostate cancer. Int J Oncol. 2011, 38: 267-277.PubMed
- Crowell JA, Steele VE, Fay JR: Targeting the AKT protein kinase for cancer chemoprevention. Mol Cancer Ther. 2007, 6: 2139-2148. 10.1158/1535-7163.MCT-07-0120.View ArticlePubMed
- Davies MA: Regulation, role, and targeting of Akt in cancer. J Clin Oncol. 2011, 29: 4715-4717. 10.1200/JCO.2011.37.4751.View ArticlePubMed
- Chen J, Somanath PR, Razorenova O, Chen WS, Hay N, Bornstein P, Byzova TV: Akt1 regulates pathological angiogenesis, vascular maturation and permeability in vivo. Nat Med. 2005, 11: 1188-1196. 10.1038/nm1307.PubMed CentralView ArticlePubMed
- Somanath PR, Kandel ES, Hay N, Byzova TV: Akt1 signaling regulates integrin activation, matrix recognition, and fibronectin assembly. J Biol Chem. 2007, 282: 22964-22976. 10.1074/jbc.M700241200.PubMed CentralView ArticlePubMed
- Somanath PR, Razorenova OV, Chen J, Byzova TV: Akt1 in endothelial cell and angiogenesis. Cell Cycle. 2006, 5: 512-518. 10.4161/cc.5.5.2538.PubMed CentralView ArticlePubMed
- Shibata MA, Ito Y, Morimoto J, Otsuki Y: Lovastatin inhibits tumor growth and lung metastasis in mouse mammary carcinoma model: a p53-independent mitochondrial-mediated apoptotic mechanism. Carcinogenesis. 2004, 25: 1887-1898. 10.1093/carcin/bgh201.View ArticlePubMed
- Gauthaman K, Manasi N, Bongso A: Statins inhibit the growth of variant human embryonic stem cells and cancer cells in vitro but not normal human embryonic stem cells. Br J Pharmacol. 2009, 157: 962-973. 10.1111/j.1476-5381.2009.00241.x.PubMed CentralView ArticlePubMed
- Fukuda S, Pelus LM: Survivin, a cancer target with an emerging role in normal adult tissues. Mol Cancer Ther. 2006, 5: 1087-1098. 10.1158/1535-7163.MCT-05-0375.View ArticlePubMed
- Fornaro M, Plescia J, Chheang S, Tallini G, Zhu YM, King M, Altieri DC, Languino LR: Fibronectin protects prostate cancer cells from tumor necrosis factor-alpha-induced apoptosis via the AKT/survivin pathway. J Biol Chem. 2003, 278: 50402-50411. 10.1074/jbc.M307627200.View ArticlePubMed
- Krajewska M, Krajewski S, Banares S, Huang X, Turner B, Bubendorf L, Kallioniemi OP, Shabaik A, Vitiello A, Peehl D, et al: Elevated expression of inhibitor of apoptosis proteins in prostate cancer. Clin Cancer Res. 2003, 9: 4914-4925.PubMed
- Amaravadi R, Thompson CB: The survival kinases Akt and Pim as potential pharmacological targets. J Clin Invest. 2005, 115: 2618-2624. 10.1172/JCI26273.PubMed CentralView ArticlePubMed
- Vaira V, Lee CW, Goel HL, Bosari S, Languino LR, Altieri DC: Regulation of survivin expression by IGF-1/mTOR signaling. Oncogene. 2007, 26: 2678-2684. 10.1038/sj.onc.1210094.View ArticlePubMed
- Munier A, Feral C, Milon L, Pinon VP, Gyapay G, Capeau J, Guellaen G, Lacombe ML: A new human nm23 homologue (nm23-H5) specifically expressed in testis germinal cells. FEBS Lett. 1998, 434: 289-294. 10.1016/S0014-5793(98)00996-X.View ArticlePubMed
- Kawamata N, Sakajiri S, Sugimoto KJ, Isobe Y, Kobayashi H, Oshimi K: A novel chromosomal translocation t(1;14)(q25;q32) in pre-B acute lymphoblastic leukemia involves the LIM homeodomain protein gene, Lhx4. Oncogene. 2002, 21: 4983-4991. 10.1038/sj.onc.1205628.View ArticlePubMed
- Hung TM, Hu RH, Ho CM, Chiu YL, Lee JL, Jeng YM, Shih DT, Lee PH: Downregulation of alpha-fetoprotein expression by LHX4: a critical role in hepatocarcinogenesis. Carcinogenesis. 2011, 32: 1815-1823. 10.1093/carcin/bgr219.View ArticlePubMed
- Bhardwaj A, Aggarwal BB: Receptor-mediated choreography of life and death. J Clin Immunol. 2003, 23: 317-332. 10.1023/A:1025319031417.View ArticlePubMed
- Sprick MR, Rieser E, Stahl H, Grosse-Wilde A, Weigand MA, Walczak H: Caspase-10 is recruited to and activated at the native TRAIL and CD95 death-inducing signalling complexes in a FADD-dependent manner but can not functionally substitute caspase-8. EMBO J. 2002, 21: 4520-4530. 10.1093/emboj/cdf441.PubMed CentralView ArticlePubMed
- Varfolomeev EE, Ashkenazi A: Tumor necrosis factor: an apoptosis JuNKie?. Cell. 2004, 116: 491-497. 10.1016/S0092-8674(04)00166-7.View ArticlePubMed
- The pre-publication history for this paper can be accessed here:http://www.biomedcentral.com/1471-2407/12/409/prepub
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.